Navigation Links
Kiadis Pharma Receives Two Orphan Drug Designations for Reviroc(TM) From the FDA
Date:12/8/2008

AMSTERDAM, December 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc(TM) Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL). One ODD has been granted for diffuse large B-cell lymphoma and the other one for the treatment of follicular lymphoma. Reviroc(TM) is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.

"This is an important strategic milestone in the development of Reviroc(TM) and we are very pleased with the orphan drug designations received from the FDA," says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The FDA's orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the United States. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the US after product approval.

About Reviroc(TM)

Reviroc(TM) is being developed as a treatment that eliminates blood cancer cells from autologous transplants for patients with end stage blood cancer. An autologous transplant uses the patient's own bone marrow to serve as a graft. Bone marrow transplants are broadly recognized as a treatment option for patients suffering from blood cancers, such as leukemia and lymphoma. One of the limitations of autologous bone marrow transplantations is the high relapse rate associated with this treatment. This is often caused by the presence of cancer cells in the transplant. Reviroc(TM) has been developed to remove tumor cells from the graft.

About Kiadis Pharma

Kiadis Pharma is an oncology focused biopharmaceutical development compan
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
2. Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
3. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 The Competitive Intelligence (CI) ... marketplace changes. CI leaders who adjust will succeed, and ... a new Best Practices, LLC study CI leaders from ... including: - Use secondary research whenever possible ... - Internal staff who are creative thinkers ...
(Date:8/29/2014)... Aug. 29, 2014 Medina Medical announced today ... member of the Board of Directors on August 18, ... development and commercialization experience, including over a decade of ... served as a Partner of the medical device incubator ... of two Foundry start-ups. Mr. Engelson previously served as ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and Markets ... Drug Pipeline Insight 2014" report to their offering. ... US is one of the largest segments of pharmaceuticals industry. ... rate, while the available therapies were unable to meet the ... the market for CNS disorder, especially over the past two ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2US CNS Disorders Drug Pipeline Insight 2014 2
... 2012 Allscripts (NASDAQ: MDRX) today announced that ... ™ to manage the revenue cycle for 39 affiliated providers ... integrated Allscripts Electronic Health Record (EHR) to automate ... the insights they need to deliver superior patient care. ...
... SAN FRANCISCO, Jan. 4, 2012  Practice Fusion, the ... community in the US, announced today that its ... a faster, simpler and more streamlined user experience ... technology flagged more than 7,000 deadly drug interactions ...
Cached Medicine Technology:Mammoth Hospital Selects Allscripts RCM Services 2Mammoth Hospital Selects Allscripts RCM Services 3Mammoth Hospital Selects Allscripts RCM Services 4Mammoth Hospital Selects Allscripts RCM Services 5Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 2Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 3
(Date:8/29/2014)... The new review that can be read on DailyGossip.org indicates ... will permanently eliminate the symptoms of this disease. , ... cure in as fast as 30 to 60 days. However, ... week. , The Tinnitus Miracle review indicates that this ... loss, pain in the ear and dizziness. Read the full ...
(Date:8/29/2014)... Cosmetic Town is a cosmetic ... plastic surgeons with prospective patients. The site showcases ... techniques in plastic and reconstructive surgery. Articles are ... reliable information for general readers, who are looking ... Town began featuring renowned cosmetic specialists from Los ...
(Date:8/29/2014)... The Nasal Polyps Treatment Miracle ... new program is actually based on some powerful ... by a former nasal polyps sufferer, who in ... problem. Manuel Richards suffered from nasal polyps for ... , Learn more about Manuel Richards' new book ...
(Date:8/29/2014)... The Department of Health and Human ... code CMS–0052–P) today allowing healthcare providers to attest for ... EHR Technology (CEHRT) or a combination of the 2011 ... not been able to fully implement 2014 Edition CEHRT ... continue to use 2011 Edition CEHRT, or a combination ...
(Date:8/29/2014)... Indosoft, Inc., a leading provider of scalable Asterisk-based ... licensing of its Q-Suite 5.7 software. As a ... been successfully deploying and supporting its ACD and Dialer ... the world for more than a decade. The introduction ... option which complements the widespread deployment of Q-Suite in ...
Breaking Medicine News(10 mins):Health News:Tinnitus Miracle Review Reveals How to Gain Tinnitus Relief in 7 Days 2Health News:Cosmetic Town Is Now Connecting Patients with Qualified Cosmetic Specialists 2Health News:Nasal Polyps Treatment Miracle Review Exposes New Natural and Permanent Healing Program 2Health News:Quirk Healthcare Outlook on MU2 Delay Confirmation 2Health News:Indosoft Offers Monthly Usage Licensing Terms 2
... of a ban on Coke and Pepsi by the Kerala Government, ... putting forth a proposal to stop the sale// and production of ... ,Top brass in the companies are very unhappy over these ... private company which is not in sync with the reports ...
... Minister Tony Abbott yesterday accused the commonwealth of bankrolling ... public money was spent.// ,He attacked ... should be able to fund public hospitals using the ... ,State health ministers, outraged at Mr Abbott's position accused ...
... too much take-away food and pile on weight will soon ... ,The National Heart Foundation's tick is a label that ... and will soon make its appearance at restaurants, take-away outlets ... by analyst BIS Shrapnel who showed that 70 percent of ...
... for one to undergo an operation.// ,A team ... analysed the outcomes of over 90,000 operations carried out at ... time to have an operation, as they had found that ... published their study in the journal Quality and Safety in ...
... eating raw shellfish have made the U.S. Food and ... raw shellfish. Reports coming// in show that oysters and ... sick across the country. ,Till date there have been ... gastroenteritis after eating raw shellfish. The illness is caused ...
... condition that affects children as well as adults. A ... alleviate// symptoms and bring down the inflammation associated with ... 10 issue of the New England Journal of Medicine. ... the National Institute of Arthritis and Musculoskeletal and Skin ...
Cached Medicine News:Health News:Health Minister Slams State Health Governments 2Health News:Heart Tick for Fast Foods in Australia 2Health News:Surgeries Performed In The Morning Have Less Post-Op Complications 2Health News:NOMID Symptoms Helped By Arthritis Drug 2Health News:NOMID Symptoms Helped By Arthritis Drug 3
... Skin Staple Remover is a plastic ... is packaged 12 units per box ... staples. The device works by slipping ... under the staple to be removed. ...
... place single staples to close surgical ... stainless steel; the staplers are not ... skin staplers to meet your needs., ... for routine skin closure in a ...
... is a full-feature skin stapler with a ... has improved visibility over existing fixed-head skin ... for easier staple placement., ,This Skin ... instrument designed to deliver rectangular, stainless steel ...
... Linear Staplers are available with either a ... instrument (non-reloadable). Each instrument contains 19 staples ... ,Benefits include: , Small profile stapling head ... , Articulating head rotates up to 80deg; ...
Medicine Products: